Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies.
Ann Clin Microbiol Antimicrob. 2015;14:19
Authors: Dunne MW, Sahm D, Puttagunta S
BACKGROUND: Dalbavancin is a lipoglycopepetide antibiotic with activity against gram positive pathogens recently approved for treatment of acute bacterial skin and skin structure infections. Pending the introduction of antimicrobial susceptibility tests, we examined the utility of vancomycin inhibitory concentrations to predict dalbavancin susceptibility in a panel of isolates obtained from phase 3 registration studies.
FINDINGS: 99.6% of Staphylococcus aureus and 99.0% of beta-hemolytic streptococci which are susceptible to vancomycin will have an MIC at or below the US FDA susceptibility breakpoint for dalbavancin.
CONCLUSION: Vancomycin should be considered as a surrogate for in vitro dalbavancin susceptibility testing.
PMID: 25885674 [PubMed - in process]